Literature DB >> 31995676

Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?

Jennifer Swainson1,2,3, Atul Khullar2,4.   

Abstract

Entities:  

Year:  2020        PMID： 31995676     DOI： 10.4088/JCP.19lr13146

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  5 in total

1.  An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.

Authors:  Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Ashok Seshadri; Larry J Prokop; Simon Kung; Kathryn M Schak; Jennifer L Vande Voort; Mark A Frye; Balwinder Singh
Journal:  Psychopharmacol Bull       Date:  2020-09-14

2.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

3.  Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.

Authors:  Jennifer Swainson; Larry J Klassen; Stefan Brennan; Pratap Chokka; Martin A Katzman; Robert L Tanguay; Atul Khullar
Journal:  CNS Drugs       Date:  2022-02-14       Impact factor: 5.749

Review 4.  The molecular pathophysiology of depression and the new therapeutics.

Authors:  Haihua Tian; Zhenyu Hu; Jia Xu; Chuang Wang
Journal:  MedComm (2020)       Date:  2022-07-21

5.  Effect of intravenous low-dose S-ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study.

Authors:  Thomas J P Mangnus; Maaike Dirckx; Krishna D Bharwani; Cecile C de Vos; Sander P G Frankema; Dirk L Stronks; Frank J P M Huygen
Journal:  Pain Pract       Date:  2021-07-24       Impact factor: 3.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.